Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...
With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...
Swiss biotech Alentis Therapeutics has secured $181.4 million, money that will be used to launch clinical trials for two ...
Are you a print subscriber? Activate your account. By Garett Sloane - 3 min 8 sec ago By Ewan Larkin - 8 min 31 sec ago By ...
Quartz on MSN11d
A new weight loss pill outperformed Novo Nordisk's versionPills are displayed with open pill bottles on top of a white counter top in the kitchen.Viking Therapeutics (VKTX) released ...
Novo Nordisk A/S (NYSE:NVO) is advancing its research on a pioneering hybrid drug, CagriSema. This drug merges semaglutide ...
A new Plantation Close EC in Tengah ~ Jointly developed by the renowned Hoi Hup Realty and Sunway Developments in a tranquil living environment dubbed as Singapore’s first ‘Forest Town’. Numerous ...
Novo Nordisk has asked the Food and Drug Administration to bar compounding pharmacies from making copies of its blockbuster weight loss drug semaglutide, arguing that the medication is too complex ...
Novo Nordisk (NVO) announced the headline results from part 1 of the ongoing ESSENCE trial, a pivotal phase 3, 240-week, double-blinded trial in 1,200 adults with metabolic dysfunction-associated ...
The global diabetes and obesity epidemic is driving another expansion of Novo Nordisk’s drug-manufacturing operations at its 264-acre campus in Clayton. The company will begin a $65 million expansion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback